179 completed, 36 terminated, 12 recruiting, 12 unknown. 252 Phase 2, 54 Phase 1, 15 Phase 3.
Follow Cystic Fibrosis: new trials by email Literature Review of Cystic Fibrosis trials Research Report on Cystic Fibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency. NHS7108, Zenpep® - Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF) | Phase 2 | Recruiting | Aimmune Nestlé Health Science US R&D, LLC | 66 | 2026-10-01 | 2026-10-01 |
| Verapamil Effect in Cystic Fibrosis-related Dysglycemia Verapamil Hydrochloride - Cystic Fibrosis Related Diabetes, Cystic Fibrosis (CF) | Phase 2 | Not yet recruiting | Rhode Island Hospital | 30 | 2026-08-01 | 2026-07-09 |
| Phase 2 Study to Assess the Safety and Efficacy of ANG003 ANG003 Dose A, ANG003 Dose B, Creon - Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF) | Phase 2 | Recruiting | Anagram Therapeutics, Inc. | 113 | 2026-04-24 | 2026-10-30 |
| Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators. Tamoxifen Citrate 20Mg Tab - Cystic Fibrosis - Complete | Phase 2 | Not yet recruiting | Azienda Ospedaliera Universitaria Integrata Verona | 35 | 2026-01-15 | 2025-12-17 |
| Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta SION-719, Placebo-to-match SION-719 - Cystic Fibrosis (CF) | Phase 2 | Completed | Sionna Therapeutics Inc. | 15 | 2025-11-03 | 2026-09-10 |
| Study With Phage for CF Subjects With Pseudomonas Lung Infection BX004, Placebo - Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF) | Phase 2 | Recruiting | BiomX Ltd | 63 | 2025-07-02 | 2025-07-22 |
| Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis Rifaximin 550 MG Oral Tablet [XIFAXAN], Placebo - Cystic Fibrosis, Abdominal Pain | Phase 2 / Phase 3 | Withdrawn | Wake Forest University Health Sciences | 2025-07-01 | 2025-06-27 | |
| A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI 3720931 (Lenticlair™-ON) BI 3720931 - Cystic Fibrosis | Phase 1 / Phase 2 | Active not recruiting | Boehringer Ingelheim | 5 | 2025-05-20 | 2026-04-14 |
| Maralixibat in Patients With Cystic Fibrosis and Constipation Maralixibat 9.5 MG/ML [Livmarli] - Constipation Chronic Idiopathic, Cystic Fibrosis | Phase 2 / Phase 3 | Recruiting | Children's Hospital Los Angeles | 20 | 2025-04-09 | 2026-04-21 |
| Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis ARCT-032 - Cystic Fibrosis, CFTR Gene Mutation | Phase 2 | Recruiting | Arcturus Therapeutics, Inc. | 33 | 2024-12-12 | 2026-05-08 |
| A Study to Test How Well BI 3720931 is Tolerated and Whether it Improves Lung Function in People With Cystic Fibrosis (Lenticlair™ 1) BI 3720931, Placebo, Inhaler - Cystic Fibrosis | Phase 1 / Phase 2 | Terminated | Boehringer Ingelheim | 5 | 2024-11-04 | 2026-04-15 |
| A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF) SP-101 and doxorubicin Cohort 1, SP-101 and doxorubicin Cohort 2 - Cystic Fibrosis | Phase 1 / Phase 2 | Recruiting | Spirovant Sciences, Inc. | 15 | 2024-09-16 | 2024-11-25 |
| A Two-Part Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Repeat Doses of Inhaled ETD001 in People With Cystic Fibrosis ETD001, Placebo - Cystic Fibrosis | Phase 2 | Completed | Enterprise Therapeutics Ltd | 57 | 2024-06-26 | 2025-11-28 |
| Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis SPL84, Placebo - Cystic Fibrosis | Phase 2 | Recruiting | SpliSense Ltd. | 64 | 2024-06-24 | 2026-05-14 |
| A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis CMTX-101, Placebo - Persistent Infection, Cystic Fibrosis | Phase 1 / Phase 2 | Completed | Clarametyx Biosciences, Inc. | 43 | 2024-06-24 | 2026-10-30 |
| Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis. Losartan, Placebo - Cystic Fibrosis | Phase 2 | Recruiting | University of Kansas Medical Center | 42 | 2024-06-03 | 2025-05-02 |
| Clinical Trial to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Adults With CF Diponecaftor, Placebo - Cystic Fibrosis | Phase 2 | Completed | Kors van der Ent | 41 | 2024-06-03 | 2025-11-24 |
| A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™) BI 1291583, Placebo to BI 1291583 - Cystic Fibrosis, Bronchiectasis | Phase 2 | Completed | Boehringer Ingelheim | 22 | 2024-04-05 | 2026-06-23 |
| A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection RSP-1502, Tobramycin inhalation solution - Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic | Phase 1 / Phase 2 | Completed | Respirion Pharmaceuticals Pty Ltd | 71 | 2024-04-01 | 2026-06-25 |
| A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF RCT2100, Placebo, Ivacaftor - Cystic Fibrosis | Phase 2 | Active not recruiting | ReCode Therapeutics | 128 | 2024-02-01 | 2026-08-19 |
Showing 20 of 252. Sign in to see all of them.
Pseudomonas Infections (16) · Exocrine Pancreatic Insufficiency (13) · Lung Diseases (11) · Genetic Diseases, Inborn (8) · Respiratory Tract Diseases (8) · Pancreatic Diseases (6) · Digestive System Diseases (5) · Asthma (4) · Infections (4) · Inflammation (4) · Respiratory Tract Infections (4) · Aspergillosis (3) · Bronchiectasis (3) · Infant, Newborn, Diseases (3)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (252) · Infant, Newborn, Diseases (249) · Digestive System Diseases (247) · Pancreatic Diseases (246) · Genetic Diseases, Inborn (244) · Respiratory Tract Diseases (244) · Lung Diseases (241) · Infections (31) · Bacterial Infections and Mycoses (26) · Pathological Conditions, Signs and Symptoms (24) · Bacterial Infections (20) · Pathologic Processes (18) · Gram-Negative Bacterial Infections (17) · Bronchial Diseases (8) · Disease Attributes (8)
ivacaftor (24) · tezacaftor (9) · Inhalation (8) · Saline Solution, Hypertonic (8) · Sodium Chloride (8) · tezacaftor, ivacaftor drug combination (8) · Sildenafil Citrate (6) · Saline Solution (5) · Tobramycin (5) · denufosol tetrasodium (5) · GLPG2222 (4) · Mannitol (4) · ataluren (4) · miglustat (4) · Aztreonam (3)
Vertex Pharmaceuticals Incorporated (22) · Boehringer Ingelheim (6) · Merck Sharp & Dohme LLC (6) · National Jewish Health (6) · AlgiPharma AS (5) · Lakefront Biotherapeutics NV (5) · The Hospital for Sick Children (5) · Gilead Sciences (4) · Insmed Incorporated (4) · PTC Therapeutics (4) · Syntara (4) · University of Minnesota (4) · Children's Hospital of Philadelphia (3) · Entero Therapeutics (3) · Johns Hopkins University (3)
United States (141) · United Kingdom (52) · Germany (45) · Canada (35) · France (32) · Belgium (30) · Netherlands (26) · Australia (23) · Italy (18) · Spain (17) · Poland (12) · Israel (11) · Ireland (8) · New Zealand (8) · Sweden (8)
Amy Schaberg, BSN (4) · Felix Ratjen, MD (3) · Gina Eagle, MD (3) · James Chmiel, MD (3) · Jennifer L Taylor-Cousar, MD (3) · Stuart Elborn, MD (3) · Eitan Kerem, MD (2) · Elizabeth Tullis, MD (2) · George Retsch-Bogart, MD (2) · Jerry Nick, MD (2) · Jochen Mainz, M.D. (2) · Larry Lands, MD (2)
PMID 33331662, PMID 37983082, PMID 32671834, PMID 31215818, PMID 36511181, PMID 31056441, PMID 33735508, PMID 36842446, PMID 37319354, PMID 10459902, PMID 15618584, PMID 15704203, PMID 15756212, PMID 17050563, PMID 17337677, PMID 17446337, PMID 18006891, PMID 18339790, PMID 18722008, PMID 18972410, PMID 19635928, PMID 19643946, PMID 19880909, PMID 19996349, PMID 20622033, PMID 20630539, PMID 20961818, PMID 21083385, PMID 21195036, PMID 21233271, PMID 21471106, PMID 21825083, PMID 21893650, PMID 21896198, PMID 22267768, PMID 22383668, PMID 22863555, PMID 22995323, PMID 23333044, PMID 23407019, PMID 23412700, PMID 23588193, PMID 23631796, PMID 23749840, PMID 24019259, PMID 24345827, PMID 24461666, PMID 24518280, PMID 24528942, PMID 24571729
2015 (5), 2008 (4), 2018 (4), 2019 (4), 2016 (3), 2017 (3), 2023 (3), 2014 (2), 2009 (1), 2025 (1), 2UM1AI104681-08 (1), M01RR000037 (1), P01HL158507 (1), R01DK057755 (1), R01HL139876 (1)